News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The International Myeloma Foundation Says IMNOVID® (Pomalidomide), The Newest Medication For Advanced Cases Of Multiple Myeloma, Is Approved For Reimbursement In Sweden, Spain, And Switzerland


7/10/2014 6:58:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) says IMNOVID® (pomalidomide), called POMALYST® in the US, is now approved for reimbursement in Sweden, Spain, and Switzerland, with decisions expected to follow in more countries in Europe. Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that typically requires multiple treatments used in sequence. Marketing authorization for IMNOVID was granted in Europe in August 2013 for use in patients after all previous treatments have failed. These new decisions mean patients in these three countries will now have access to this therapeutic through their government health programs.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES